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Extracellular Vesicles (EVs) are gaining interest as central players in liquid biopsies, with potential appli-
cations in diagnosis, prognosis and therapeutic guidance in most pathological conditions. These nano-
sized particles transmit signals determined by their protein, lipid, nucleic acid and sugar content, and the
unique molecular pattern of EVs dictates the type of signal to be transmitted to recipient cells. However,
their small sizes and the limited quantities that can usually be obtained from patient-derived samples
pose a number of challenges to their isolation, study and characterization. These challenges and some
possible options to overcome them are discussed in this review.
1 Introduction
Extracellular Vesicles (EVs) are involved in the transmission of
biological signals between populations of prokaryotic and
eukaryotic cells. As central mediators of intercellular com-
munication, EVs are involved in many cellular processes, such
as compensating for stress conditions, triggering physiological
responses that contribute to the maintenance of cellular integ-
rity, organismal homeostasis1–3 and regulating a range of bio-
logical activities. Their potential applications for diagnosis
and guiding therapeutics, as well as determining prognosis of
pathological conditions has allowed the field of EV-studies to
grow steadily in recent years.
The term EVs, coined by the International Society for
Extracellular Vesicles (ISEV, http://www.isev.org), categorizes
vesicles based on their biogenesis or release pathway, and
include exosomes (50–100 nm in diameter), originated from
the endocytic pathway and with buoyant densities of 1.11–1.19
g mL−1,4 shedding microparticles/microvesicles (100–1000 nm)
released directly from the plasma membrane,5 apoptotic blebs
(50 nm–2 μm; produced as a consequence of indiscriminate
apoptotic disintegration),6 large oncosomes (1–10 μm)7 and other
miscellaneous EV subsets.8 As the sizes of the diﬀerent EVs-
subsets overlap, as well as their cargo, several groups have now
started characterizing the composition of EV-subtypes. Recent
papers claim successful subclassification of EVs based on
general surface proteomic profiling,9,10 or on transcriptional pro-
files of individual EV populations.11,12 EV subtypes have been iso-
lated by a number of means, including recovery at diﬀerent cen-
trifugation forces, diﬀerent filters, at slightly diﬀerent positions
in density gradients, via immuno-isolation by diﬀerent surface
molecules, chromatography or by flow cytometric sorting.
At present, functions of EVs have not been fully elucidated.
However, they appear to be able to modulate host–pathogen†Equal contribution.
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interactions13 and to contribute to several pathological con-
ditions such as infectious and inflammatory diseases, neuro-
logical disorders and cancer. EVs are particularly important in
clinical settings, largely because they contain a wealth of bio-
markers that can be used to monitor clinical status, chemo-
therapy-response,14 disease progression,15 and many relevant
and diverse clinical conditions. The composition of EVs is not
random and each EV-cargo delivers specific molecular mess-
ages. Indeed these nanosized membrane vesicles transmit
signals by proteins, lipids, nucleic acids, and sugars, and the
unique molecular pattern of this package dictates the type of
extracellular signal to be transmitted to recipient cells.1
Despite the promise of revealing informative markers of
medical interest, working with these small particles poses
many technical challenges. In addition to the concerns over
data analysis, there are further uncertainties over protocol
standardisation and how to define the pre-analytical and
analytical variables that impact upon outcome measures.16
The aim of this review is to outline the most relevant chal-
lenges related to working with EVs, specifically discussing the
advantages and disadvantages of diﬀerent approaches and
suggesting alternative routes to better overcome frequent
issues. A detailed scheme of EV purification and characteriz-
ation methods is presented in Fig. 1.
2 Pre-analytical factors
2.1 EVs derived from biofluids
EVs have been isolated from diverse biofluids including
blood,17 urine,18 saliva,19 breast milk,20 cerebrospinal21 and
ascitic fluids,22 gastric juice,23 bile,24 sputum,25 bronchoalveo-
Fig. 1 Scheme of EVs isolation, quantiﬁcation and characterization, including the analysis of EVs molecular content. The superscript numbers on
the ﬁgures indicate the need of each step as follows: 1 – to ensure intravesicular origin of RNAs; 2 – to remove abundant ribosomal RNAs that may
be present as fragments in EVs, and therefore not visible by Bioanalyzer analysis; 3 – cDNA synthesis may be performed with transcript-speciﬁc or
general primers; cDNA pre-ampliﬁcation before real time PCR is optional; 4 – to break down long RNA molecules; 5 – to separate small RNAs (<200
nt) from long RNAs (>200 nt); 6 – to tag molecules from diﬀerent samples and enable multiplex analysis.
Review Nanoscale
882 | Nanoscale, 2018, 10, 881–906 This journal is © The Royal Society of Chemistry 2018
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
3 
D
ec
em
be
r 2
01
7.
 D
ow
nl
oa
de
d 
on
 9
/1
4/
20
18
 9
:1
4:
09
 A
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
lar lavage,26 semen27 and tears.28 The viscosity of these fluids,
as well as their fat and protein content are highly variable,
which may aﬀect EVs purity and yield and, therefore require
the protocols to be adjusted according to the biofluid of inter-
est. Standardized pre-analytical steps are crucial to minimizing
artefacts in EV-analysis, particularly when EVs are derived
from complex body fluids such as blood. The amount, purity
and content of biofluid-derived EVs may be aﬀected by numer-
ous factors including age, gender, ethnicity, body mass index,
disease, use of medications, general lifestyle, and dietary
habits.29 Ideally, these factors should be taken into account
and normalized across all study subjects (patients and any
relevant controls).
Other important considerations include methods of blood
collection, as shear force may induce hemolysis, which has
been shown to alter the expression of some plasma miRNA
molecules30 and may also aﬀect EV-derived content. Whereas
EV counts appear to remain stable overtime in samples stored
with no agitation, gentle agitation (used to simulate blood trans-
portation) leads to an artificial and strong release of platelet-
derived EVs.31 Additionally, anticoagulants have been shown to
be capable of preventing the formation of EV-blood cell aggre-
gates (aggregation was reduced in EDTA-preserved blood).32
Blood preserved with EDTA also appears to reduce the above-
mentioned agitation eﬀects on platelet-derived EVs if compared
to citrate or heparin. Storage time is another important factor:
Fendl et al. 2016 found comparable amounts of EVs in freshly
drawn blood (collected in heparin, EDTA or citrate) but
increased amounts of EVs were observed after 3 h storage, in an
anticoagulant-dependent fashion, with increments varying from
2× (EDTA) to 10× (citrate), primarily due to platelet-derived
EVs.31 Also critical is the careful separation of platelets from
plasma with adequate centrifugations; the International Society
on Thrombosis and Haemostasis recommends blood collection
in citrated tubes and two successive centrifugations at 2500g for
15 minutes at room temperature.33 However, EDTA has been
recently suggested as a valuable option in clinical settings.32
Another factor that needs to be considered when selecting
EVs isolation protocols across diﬀerent biofluids is the volume
of starting material, as some biofluids may need to be concen-
trated prior to EVs isolation such as urine, an important
source for patients diagnosed with renal pathologies, prostate
and bladder cancers,18 and other conditions including the
parasitic infection schistosomiasis.34 A recent study compared
several filters and concluded that the best for recovering EVs
from plasma, urine and EV-spiked PBS was a regenerated cell-
ulose membrane with pores capable of retaining particles
above 10 kDa.35 Liang et al., have also demonstrated the feasi-
bility of concentrating the EVs using a double-filtration micro-
fluidic device capable of isolating, concentrating and quantify-
ing urinary EVs, using 8 mL of the pre-filtered (0.22 μm filter)
and 20 000g centrifuged urine-supernatant collected from
bladder cancer patients and controls.36 Using this approach
the authors demonstrated that the principle of size-exclusion
using two polycarbonate membranes (with pore sizes of 200
and 30 nm) permitted the concentration of EVs within this
size-range and the later study of CD63 expression using ELISA.
Urine-derived CD9-positive exosomes have also been isolated
using magnetic beads37 and Gilani et al. have also shown that
digital flow cytometry can be a good approach for quantifying
the expression of markers of interest in urine-derived EVs from
renal-injury patients.38
Besides biofluid-volume, specific methodological para-
meters need to be optimised during EVs isolation according to
their inherent biochemical properties. For example, the pellet
of EVs isolated from breast milk by 100 000g ultracentrifuga-
tion was found to be too solid to resuspend, because of the
high abundance of whey and casein protein in milk.39 One
proposed solution was to purify the 10 000g supernatant
through an overnight sucrose density gradient, allowing separ-
ation of EVs from protein complexes.39
2.2 Cell culture conditioned medium
The use of cell culture conditioned medium enables a more
controlled environment for EV isolation. Nonetheless, there
are important aspects that may directly influence EV yields
that should be considered. The choice between culture
medium containing EV-depleted fetal bovine serum (FBS)
versus culture medium with no FBS (serum starvation of cells)
needs to be considered. This choice implies that an abrupt
change to serum-free medium will likely cause a major stress
to cells and lead to altered EV secretion.40 On the other hand,
rigorous EV depletion of FBS needs to be thoroughly per-
formed, using long ultracentrifugation protocols (16 h at
≥100 000g) in order to maximize the removal of FBS-derived
EVs.41–43 Recent evidence, however, suggests that even this
extended ultracentrifugation cannot remove contamination
from bovine small RNAs, some of which can be mis-annotated
as human RNAs.44 Apoptosis-induction control experiments
can also be performed to exclude the possibility that EVs, and
consequently the putative isolated EV-RNAs, are due to cell
death,45 especially as many experiments report changes in
RNAs upon EV induction as opposed to the steady-cell state.
Other factors that need to be carefully considered include cell
culture matrices and plastics, exact culture medium compo-
sition/volume, cell passage, cell confluency and viability, myco-
plasma-status and other microbial contamination. If con-
ditioned medium will be stored before EVs isolation, it is
crucial to clear it of cells and cellular debris by centrifugation
before freezing, and to minimize subsequent thaws.
2.3 Storage of EVs
Lőrincz et al. performed a detailed analysis of the eﬀect of
storage in diﬀerent conditions (+20 °C, +4 °C, −20 °C, −80 °C
for 1, 7 or 28 days) on the physical and functional properties
of EVs derived from human neutrophilic granulocytes.46 Flow
cytometry, dynamic light scattering and electron microscopy
were used for measuring EVs physical properties (number, size
and morphology), and an antibacterial assay was used to test
the functional property of EVs. They found that storage (even
at −20 or −80 °C) significantly altered the functional pro-
perties of EVs, although their number and morphology stayed
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constant. In another study, a 7-fold increase in the number of
phosphatidylserine-exposing EVs was found in EVs isolated
from plasma samples that had undergone a single freeze–thaw
cycle, suggesting changes in the vesicle membrane phospho-
lipids, whereas in urine-derived EVs the same eﬀect was not
observed.47 Kalra et al. spiked EVs isolated from a colorectal
cancer cell line into plasma samples and measured TSG101
protein expression after 10, 30 and 90 days in storage at 4 °C,
−20 °C or −80 °C, as well as PKH67 dye labeling and uptake by
cells (−20 °C for 30 days).48 They found that all storage con-
ditions yielded EVs with detectable TSG101 and capable of
being transferred into cells.
Although several studies have investigated whether storage
impacts specific characteristics of EVs, there is a lack of large-
scale analysis of EVs cargo changes that may be caused by
storage. To the best of our knowledge, no study has evaluated
transcriptomic, proteomic and lipidomics alterations that may
be induced upon EVs storage. Until more in-depth “omics”
studies are performed, in addition to functional assays, the
understanding of the true stability of EVs remains incomplete.
In this sense, we recommend EVs to be evaluated as soon as
possible after their isolation, especially for functional studies,
avoiding repeated freezing and thawing cycles.
3 EV isolation protocols
There are several EV isolation and characterization techniques
available, and each has its own set of pre-analytical factors that
may influence yields. The ISEV has issued several position
papers highlighting the importance of standardization of
sample collection and EV isolation and characterization
methods, which summarize all the detailed information that
should be recorded and provided in publications.40,49,50
Launched recently, the EV-TRACK database (http://evtrack.
org) is an excellent initiative in the EV-research field to encou-
rage standardization of vesicle isolation and characterization
methods.51 This initiative was created by an international con-
sortium of 92 researchers from 12 countries, who evaluated and
scored the experimental parameters of 1226 recently published
EV-related articles. The EV-METRIC is a summary score of the
article’s adherence to and detailed reporting nine experimental
parameters. The fact that the average EV-METRIC across all bio-
fluid studies is only 20% indicates how the heterogeneous
EV-field is currently deficient in methodological reporting. The
online database is searchable, allowing easy identification and
comparison of EV-related articles. Another interesting feature is
that the authors can annotate their study’s database entries,
adding experimental details that may have been overlooked
during publication. Hopefully, EV-TRACK will contribute to
better transparency and reporting in EVs publications, allowing
improved interpretation and reproducibility of experiments.
3.1 Ultracentrifugation (UC)
The selection of an EV-isolation method largely depends on
the source of sample. For less complex samples obtained from
cell cultures, it is beneficial to use diﬀerential UC with no pre-
liminary steps, an approach that has long been considered the
most eﬃcient EV isolation technique. New isolation methods
appear often, usually involving column enrichment or precipi-
tation. However, the most popular primary isolation methods
still in use are based on UC.52 On the other hand, isolation of
EVs derived from complex biological fluids may benefit from
the use of multiple methods to remove specific components
(e.g. platelets, lipoproteins or protein complexes) before UC,53
or even alternative isolation methods, involving column
enrichment, sequential filtering or precipitation. However, as a
means of first EV-isolation step, UC is a cost-eﬃcient and
widely accepted way to isolate EVs.52
The isolation of EVs through diﬀerential UC relies on
several centrifugation steps with increased centrifugal force to
produce sequential pellets of cells and cell-debris (300–1000g),
microvesicles (10 000–20 000g) and exosomes (100 000g). Some
have described the use of serial ultrafiltration through 0.22
and 0.45 μm filters before pelleting54 and variation of the cen-
trifugation forces have been implemented in diﬀerent
protocols.
Advantages of UC include low cost – as ultracentrifuges are
readily available in many labs – and the capacity to spin a wide
range of volumes from a few millilitres up to >100 mL.
However, there are a number of problems associated with iso-
lating EVs by UC. One of the major caveats is the co-purifi-
cation of non EV-associated proteins, particularly protein
aggregates and lipoproteins,55 which may be interpreted as
integral or enriched EV components in downstream analyses.
Ultrafiltration can be coupled with UC to reduce EV-protein
aggregates.56 Attention should be given to centrifugation
forces applied to EVs. Nordin et al., have shown some degree
of EV disruption after UC for 70 min at 120 000g.56 Therefore,
when the recovery of intact EVs using UC is an aim, we rec-
ommend the use of a maximum of 100 000g.
3.2 Density gradients (DG)
An approach that is commonly used to overcome the problem
of co-purification is to follow UC with further purification of
EVs in a sucrose DG which makes use of EV density for better
separation (26). EVs of a particular size and origin have a par-
ticular floatation density, usually in the range of 1.08–1.22
g mL−1.57 Several protocols have been described,58 the majority
of which involve resuspending an EV-enriched pellet following
UC, overlaying a sucrose gradient in various buﬀers which may
also contain deuterium oxide, performing UC again and col-
lecting the appropriate fractions which are enriched in EVs.
Diﬀerential UC shows the presence of larger vesicles by laser
particle size measurement, and protein concentration studies
show that DG UC yields higher protein concentration and
more target exosome proteins.59
Unfortunately, diﬀerential UC can be a lengthy process with
the most time taken for the UC itself. For clinical grade data or
highly enriched samples it is recommended to use multiple
centrifugation speeds that will considerably lengthen the
process, reducing its applicability for clinical settings.60
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Whereas sucrose gradient UC is relatively time consuming, it
undoubtedly results in the isolation of purer EV samples than
UC alone.59 However, due to fractionation a relatively high
starting concentration of EVs is required.61 Besides being able
to isolate purer EVs, it should be noted that contaminants that
have the same density of EVs, such as some viruses,62 plasma-
derived high- and low-density lipoproteins63,64 and uromodu-
lin and albumin65 from urine, are likely to contaminate the
EVs isolated by DGs. It has been shown that the similar floata-
tion densities of HIV virus particles and EVs make them
indistinguishable by conventional gradient separation.66
Presumably, the co-purification of EVs and virus particles
could be considered a universal problem due to common viral
contaminations of cell cultures which go undetected. Cantin
et al. found that it was possible to separate HIV particles
and EVs using commercially available OptiPrep DG solution.66
This employs a gradient of iodixanol rather than sucrose,
and has been used for isolating fractions of pure EVs for
proteomic analysis from conditioned cell culture medium67
and plasma.48
3.3 Immunoaﬃnity
An approach to improve the purity of the EVs population is to
use immunoisolation, whereby EVs preparations are incubated
with antibody-coated latex17 or magnetic beads,68 allowing
their separation based on the expression of markers of inter-
est. This technique has the potential to specifically pull-down
EVs with a particular surface marker while excluding contami-
nating particles or other EVs populations. A study comparing
immunoisolation with DG separation and UC for the isolation
of human colon cancer-derived EVs showed that immunoisola-
tion produced the highest EVs yield as measured by quantitat-
ive protein mass spectrometry.61
As immunoisolation is not compatible with large-volume
samples, samples with low EV content must be concentrated
prior to incubation with antibody-coated beads. Therefore,
immunoisolation is commonly used as an additional purifi-
cation step following conventional EVs isolation from large
sample volumes using UC and possibly DG,17 making this a
lengthy procedure. When small volumes of starting material
contain suﬃcient EVs to isolate and analyse (as with serum),
immunoisolation can be used to isolate EVs directly.69
Importantly, when isolating EVs from serum, it is essential to
pre-coat the beads with a molecule such as sulfobetaine to
reduce the non-specific adsorption of abundant serum pro-
teins. This single-step EV isolation technique may prove to be
a valuable diagnostic tool for identifying disease markers in
EVs.69,70
While one of the key advantages of immunoisolation is its
specificity based on the chosen antibody, this approach may
also be limiting since it is likely to isolate merely a sub-popu-
lation of EVs. There is still poor understanding of which EVs
markers are present on diﬀerent EVs subpopulations, and
what the subcellular and cellular origins of these EVs are. For
example, there are no accepted, exclusive markers to dis-
tinguish between exosomes and microvesicles despite their
distinct mechanisms of biogenesis.71 In a diagnostic setting,
the best case scenario would be to have a cell-type specific
surface markers which are diﬀerentially regulated during
disease and released in EVs as recently reported.68
While immunoisolation has been successfully used for ana-
lysis of EVs by mass spectrometry61 and RNA sequencing,72
the use of immunoisolated EVs in functional studies is more
diﬃcult due to the challenge of dissociating high yields of
active EVs from the beads. Chaotropic agents such as NaCl
have been successfully used to elute EVs from beads where
EVs have been shown to retain at least some functionality.73
However, in spite of successful elution of EVs using mild con-
ditions, small changes in EVs size and surface structure can
occur.74,75 Thus, care must be taken when interpreting results
from functional analyses using immunoisolated EVs.
3.4 Microfluidics
Microfluidics technologies can be used to isolate EVs popu-
lations of interest. Here, molecules enriched in the EVs mem-
brane, such as specific lipids and proteins, can be used to
isolate them.69 Many groups have already described the use of
customised on-chip devices to isolate EVs, partly because this
approach enables the use of low input sample. Another impor-
tant point is the feasibility of EVs evaluation directly from
bodily fluids (without the need for prior extraction steps),
which can be of particular interest in the diagnostic setting.76
Combining microfluidics with previously described immu-
noaﬃnity has resulted in an immunoaﬃnity microfluidic
device based on CD63, an abundant tetraspanin present in the
EVs membrane.77 More recently, the Exochip, another on-chip
device allows not only EVs isolation based on CD63 immuno-
aﬃnity, but also their quantification by fluorescent dye
staining.78
EV features, such as electric properties, shape, size and
density, can also be exploited in the development of custo-
mised chips.79 As a note of caution we must state that it
remains to be demonstrated if antibody-isolation approaches
somehow modify the cargo or the functionality of EVs and if
their biological activity is dependent on the simultaneous sig-
nalling given by a more diverse EVs set, that can not be iso-
lated by specific antibodies.
3.5 Size exclusion chromatography (SEC)
EVs with diﬀerent sizes can be separated using Size Exclusion
Chromatography (SEC), a technique that has been more and
more used currently, allowing the recovery of pure vesicles
with increased functionality, purity and integrity. Advantages
of SEC include the reduction of EVs-aggregation during the
isolation procedure,56 the eﬃcient separation of EV from
soluble proteins and capability of isolating pure, intact and
biologically active EVs.80 SEC removes 99% of the soluble
plasma proteins and >95% of HDL from the purest fraction of
EVs, does not induce aggregation of EVs, and retains the integ-
rity and biological activity of EVs.56,80–82 Contaminants such as
von Willebrand factor and LDL are unexpected based on par-
ticle size, but these can still be found possibly complexed
Nanoscale Review
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to EVs.63,83 SEC allows the EVs environment to be changed,
such as from plasma to buﬀer, with no or minimal detrimental
eﬀects on EVs themselves. Also, it is fast, 10 to 20 minutes per
sample, and relatively inexpensive,84 which makes it more
applicable in a clinical setting. A disadvantage of SEC is the
dilution of EVs sample, which often requires second step i.e.
re-concentration of EVs by ultrafiltration.56,80,81,83–86
Compared with DC, EVs isolated by SEC have a high yield of
biophysically intact EVs although at the expense of
dilution.56,86 A single-step plasma EVs isolation using SEC has
been published, based on the use of qEV SEC columns, an
eﬃcient system to isolate EVs from plasma proteins.60,84 Also,
instead of pelleting EVs by UC, as used by some, the appli-
cation of protein concentrating devices allows the fast concen-
tration of EV fractions.60,84 This provides an eﬃcient means of
isolating and concentrating EVs from human plasma, while
avoiding some negative issues related to UC as previously men-
tioned. SEC and ultrafiltration can be coupled to provide
higher EVs purity and good recovery rates, while still preser-
ving their biophysical and functional properties.56
Ultrafiltration of cultured media results in higher recovery of
EVs after DG purification, and is a faster alternative to UC,
whereas the SEC outperforms precipitation of EVs isolated
from human plasma.60
3.6 Ultrafiltration (UF)
Filtration-based EVs isolation methods can be used indepen-
dently or in conjunction with other techniques such as UC.
Advantages of filtration-based methods are the ability to use
variable sample input volumes, simplicity and low cost. Davies
et al. developed a microfluidic filtration system for isolation of
EVs directly from unprocessed whole blood55 which allowed
the study of very limited amounts of blood from melanoma-
bearing mice. After being isolated from a few microliters of
blood by this pressure-based device, the EVs were shown to
retain their intact morphology and to express Melan A mRNA,
a melanoma tumor marker, as well as other classic EV-markers
(as evidenced by Western blot of CD9, CD63 and CD81).
Interestingly, a direct comparison with EVs isolated by UC was
performed, and TEM analysis showed that UC caused many
EVs to aggregate and to deform, which did not occur in the fil-
tration-derived EVs, even under pressure.55 A three-step
sequential filtration-based protocol allowed the isolation of
EVs from larger volumes, such as 150 mL of cell culture con-
ditioned medium.87 The authors conclude that sequential fil-
tration with a 100 nm cut oﬀ final filtering step enriches for
exosome-sized vesicles (81% compared to 23% for UC),
suggesting that UC may lead to co-purification of larger vesi-
cles and/or protein aggregates. UF is more appropriate with
volumes in excess of 400 mL due to the higher flow rate, and
that EVs loss is only observed with the first 50–100 mL of cul-
tured media.60 Whereas it is far more time eﬃcient than cen-
trifugation methods, taking only 20 minutes to concentrate
over 150 mL of sample compared to 2 rounds of UC for
90 minutes each.60 Importantly, UF can have a recovery of up
to 80% and may concentrate EVs up to 240-fold.60 This implies
that UF-based methods are eﬀective to concentrate EVs.
However, UF has some limitations such as it may result into
non-specific binding of EVs to membranes35,56 and thus may
present some loss of EV yield owing to trapping in filter pores.
3.7 General aspects of EVs isolation methods
Coincident with the EV-TRACK initiative, several groups have
compared methodologies to improve the eﬃciency of the iso-
lation and characterization of EVs. Even being considered gold
standard for purification, diﬀerential centrifugation can
provide technical diﬃculties to process large volumes of con-
ditioned medium and it has been suggested that repeated UC
steps can damage vesicles and reduce yield, impacting proteo-
mic and RNA studies.56 In this sense, the group of Dr Andreas
Moeller (QIMR Berghofer Medical Research Institute,
Australia) compared UC to UF for the isolation of exosomes
from cell culture conditioned medium and concluded that the
later provided faster and better recovery.60 They then further
compared four alternative methodologies (two precipitation-
based methods: ExoQuick and Exo-spin; one SEC-based
method: Izon qEV columns; and one DG purification-
based method: Opti-Prep), concluding that precipitation-
based methods led to higher particle yield but less purity
(measured by particle to protein ratio), while qEV columns pro-
vided the purest preparations, including also plasma-derived
exosomes.
A recent work has compared four exosome isolation proto-
cols (single-step UC) and density-gradient UC-based protocols
using iodixanol (Optiprep) and two commercially available pre-
cipitation-solution based protocols EXO-Quick (EQ) and total
exosome isolation (TEI).88 The results showed Optiprep to be
the method of choice in terms of removing EV-associated
protein/RNA complexes contaminants, allowing the recovery of
exosome-specific proteins and RNA.88 This was reinforced in a
clinical study on plasma exosomes where Optiprep gradient
centrifugation was the single method capable of removing con-
taminating plasma proteins.48 Regarding the quality of the
RNA, Van Deun et al. found several diﬀerences of RNA profiles
between the methods, and strongly recommend to validate iso-
lation methods prior to consider exosome-specific content,
functions and biomarkers.
Moreover the group of Dr Pieter Vader (University Medical
Center Utrecht, The Netherlands) and Samir El Andaloussi
(Karolinska Institutet, Stockholm, Sweden), provided evidence
that SEC-isolated EVs better retain their functional activities,
as compared to UC-isolated EVs.89 They investigated diﬀer-
ences in functionality of cardiomyocyte progenitor cell derived
EVs isolated using UC and SEC, concluding that SEC-isolated
EVs were more eﬃcient in stimulating the migration of endo-
thelial cells, having EV-induced ERK1/2 phosphorylation as a
measurement to compare the UC-EVs and SEC-EVs
functionality.
Reinforcing the importance of UF the group of Dr An
Hendrix (Ghent University, Belgium) compared five commonly
used filters for their eﬃciency to recover exosomes from clini-
cal samples.35 Regenerated cellulose membrane filters, with
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pores of 10 kDa, showed higher eﬃciency. They also compared
colorimetric and fluorimetric kits to measure EV protein
content, and found the Qubit fluorometric assay to be the
most sensitive (considering the lower BSA standard of 200
µg mL−1) and the more consistent in terms of quantification
among technical and biological replicates. This group also
suggested the Optiprep (Sigma Aldrich) to be the best method
to isolate EVs and proposed a protocol to remove Optiprep left-
overs from EVs. Other eﬀorts have been done by Dr Marca
Wauben’s group (Utrecht University, The Netherlands) who
developed a fluorescence-based flow cytometric high-through-
put method for quantitative and qualitative analysis of nano-
sized cell-derived membrane vesicles (50–100 nm) which
cannot be visualized by conventional scatter-based analysis.90,91
In order to ensure how pure are the EVs isolated by any of
the possible protocols, the ratio of EVs and non-EV com-
ponents can be assessed. One of the most used methods is the
determination of the number of EVs per microgram of
measured proteins in the isolated EVs. EVs purified using
sucrose DG from conditioned cell culture media provided
highly purified EVs: 3.3 × 1010 particles per µg protein.
However, when isolated from biofluids EVs are much more
contaminated by proteins giving ratios around 6.5 × 109 par-
ticles per µg protein for fresh serum and 1.1 × 109 particles per
µg protein for fresh urine.92 This calculation should be inter-
preted with caution as the ratio depends on the source of the
vesicles as well as the method of extraction.88
4 Characterization of the isolated
EVs
After isolation, EV populations need to be characterized for
intended downstream applications, for which there is a variety
of techniques available. This section will discuss some of the
available options in light of the instrumental parameters of
each technique.
4.1 Electron microscopy (EM)
The use of electron microscopy (EM) has considerably pushed
the field of EVs and enabled the discovery of apoptotic vesi-
cles, microvesicles and exosomes. The nanometer-scale resol-
ving power of transmission electron microscopes has, however,
its drawbacks, which include lengthy sample preparation, lack
of multi-parametric phenotyping, and low throughput
capacity. These characteristics make large EM studies rather
challenging, with the amount of starting EVs material being
particularly critical. Yet, morphological characterization using
parameters such lipid and protein compositions, cellular
origin, size, density and morphology4 is a key step for classifi-
cation of isolated EVs. Thus, eﬀorts to mitigate the challenges
in the use of electron microscopy to study EVs are most
welcome in the field.
One of these common challenges relates to the amount of
available material for transmission EM preparation, micro-
tomy and visualisation. Some tissues and body fluids release
an abundant amount of vesicles that are easily harvested by
diﬀerential centrifugation or aﬃnity purification chromato-
graphy. However, most often than not, isolated EVs are few and
far between; and sample preparation itself can at times cause
further loss of material. In an attempt to overcome this issue,
recently there have been informal discussions, in conferences
and focused meetings, about the use of proteinaceous material
(e.g. matrigel, bovine serum albumin, or other inert protein) to
‘encapsulate’ EVs in a rich protein surrounding that is exten-
sively cross-linked during fixation. This is because the protein
around EVs, when cross-linked together, will form a firm
matrix around the vesicles, protecting them from falling apart.
Alternatively, the use of inert polysaccharides (e.g. agarose,
agar, methylcellulose) to embed isolated EVs in a small piece
of gel prior to EM processing has also been reported by indi-
vidual laboratories with success.
A routine EM method that has been used with great success
for the study of EVs is that of negatively-stained whole mount
preparation.4 Here EVs are adsorbed onto a filmed metal grid,
chemically fixed and negatively stained prior to observation
using a transmission electron microscope. Whole mounts are
extremely useful for morphological analysis (e.g. EV size,
shape, density), and can be combined with immunolabelling
techniques. This method is particularly useful for the identifi-
cation and localisation of immunological epitopes on the
external surface of EVs, whereas EV-internal epitopes are
better visualised by positive staining methods.
Nevertheless, the visualisation of EVs by transmission elec-
tron microscopy, coupled or not with immunolocalisation
techniques, suﬀers mostly from two major challenges: lack of
contrast and preservation (of vesicle morphology and/or mole-
cular epitopes). This is particularly critical when considering
the potential of EVs as biomarkers in medical applications.
Some whole-mount preparations yield cup-shaped exosomes,
which has been suggested to be an artefact caused by sample
dehydration.93 Indeed, the preparation steps of chemical fix-
ation, dehydration, observation under vacuum, and electron
beam radiation damage could all interfere with an important
feature of exosomes, that of size.94,95
Cryo-electron microscopy (cryo-EM) comes at hand here,
and hydrated exosomes studied by cryo-EM have been reported
as close-to-spherical nanoparticles.96,97 As fixation tends to be
physical (cryogenic) rather than chemical, cryo-EM is thought
to preserve EVs closer to their native state,98 in particular in
terms of their morphology and immunological epitopes used
in the identification of vesicle biomarkers. An interesting
feature described in cryo-EM of exosomes from prion-infected
cells was the presence of a second, internal membrane-bound
region of denser core and, in many cases, of hexagonal
shape.97 Vesicles derived from human plasma and studied by
the same method also show a variety of forms and sizes,
suggesting multiple membrane profiles in EVs. Elongated vesi-
cles, empty or not, were also observed, and so were EVs sur-
rounded by smaller spherical structures.99 Yet, because most
cryo-EM procedures do not include the use of heavy metals,
contrast of the material could be compromised if not for
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various optical and diﬀraction techniques – the work of col-
leagues such as Alain Brisson from the Institut de Chimie &
Biologie des Membranes & des Nano-objets (CBMN, Bordeaux,
France) in the development of suitable imaging analysis
methods, and of diagnostic assays using EVs, holds much
promise here.
4.2 Nanoparticle tracking analysis (NTA)
NTA is a light scattering technique that makes use of both
laser light scattering and the Brownian motion of particles to
obtain the particle size distribution and concentration. This
approach takes into consideration the particles’ speed in a
medium of known temperature and viscosity and allows the
calculation of its hydrodynamic diameter. The first studies of
EVs using NTA were published in 2011.100 NTA is currently the
most popular quantitative method of EV analysis.52 This is
because few other high-throughput techniques have the appro-
priate resolution for single EV particle analysis. Whilst NTA
allows relatively high throughput, and claims to have resolu-
tion down to small diameters, its ability to size and determine
concentration accurately is however debatable.101 Moreover,
when performing NTA measurements, before dilution of
samples, attention should be given towards the lack of particu-
late matter in suspension buﬀers (usually phosphate buﬀered
saline) to avoid artificial inflation of EV counts. The addition
of a detergent such a Triton X to NTA preparations allows for
confirmation of EV-lipid moieties. Its fluorescent mode is also
capable of providing specific results for labelled particles. In a
recent application of fluorescent NTA, it was shown the use of
miRNA-specific molecular beacons encapsulated in cationic
lipoplex nanoparticles that fuse non-specifically with nega-
tively charged EVs and this allowed the precise quantification
of EVs carrying an specific miRNA and how many copies of
this miRNA could be found in these EVs.102 This paves the way
to future therapeutic applications that rely in the identifi-
cation/quantification of specific markers.
4.3 Resistive pulse sensing (RPS)
RPS utilises the Coulter principle to determine the absolute
diameter and distribution of particles in a suspension in the
range of ∼50–10 000 nm.101,103 RPS utilised in the EV field is
generally carried out using the qNano (Izon Science Ltd,
Christchurch, New Zealand). The qNano consists of two fluid
cells separated by a non-conductive membrane. An electric
current is passed through a single pore in the membrane and,
as particles pass through this pore, a transient attenuation of
signal occurs that is approximately proportional to the particle
volume. This system is calibrated using beads of a known dia-
meter and concentration.104 Sample volumes in the qNano can
be as low as 10 μL. By applying pressure diﬀerences between
the fluidic cells, pressure-driven flow overcomes the flow pro-
duced by diﬀusion, electrophoresis and electro-osmosis.
Disadvantages of this technique include: multiple pore sizes
are required to measure the full EV size range; pores are prone
to clogging; little phenotypic information regarding the EV’s
derivation is gained; identifying EVs from similar sized con-
taminants is not possible.
4.4 Flow cytometry (FCM)
Although mostly used for cellular analysis, FCM is currently
one of the most popular techniques used to study EVs, in par-
ticular microvesicles.105 Flow cytometers that have been devel-
oped for dedicated EV analysis, referred to as dedicated FCM
(dFCM), have been shown to be capable of resolving particles
consistent with biological vesicles to <30 nm. dFCM are
usually conventional flow cytometers that have been custo-
mised by a laboratory, although more recently they have also
become commercially available.106–108 A persistent concern in
FCM is the ability to reliably distinguish between EVs that
carry a specific protein marker from those that do not, and
thus to accurately measure the proportion of EVs of a certain
type. Quantitative and qualitative analysis of EVs populations
present within a sample are needed. Although being a pre-
requisite for a correct data interpretation, the use of proper
controls that robustly validate the test samples and establish
background levels are generally missing.109 Fluorescently-
stained polystyrene microspheres have been used as a stan-
dardisation method for EV analysis, yet their high refractive
index compared to EVs means that they cannot reliably be
used to directly approximate the size of EVs using FCM scatter
parameters. Furthermore, due to FCM collecting light at
diﬀerent angles, scatter resolution cannot be compared using
polystyrene microspheres without the use of refractive index
normalisation using laser scatter physics modelling.110
Fluorescent sensitivity can be quantified using microspheres
that have a known quantity of molecules of equivalent soluble
fluorophore (MESF) that are recommended for standardising
EV analysis. Reviews dedicated to EV standardisation using
FCM can be found elsewhere.105
5 Characterization of EV content
5.1 Characterization of EVs content: RNA
5.1.1 RNA purification. Several sources of bias due to
diﬀerences in experimental methodologies may explain discre-
pancies between results of EV-studies, including EV-RNA
related analysis. The two main RNA purification approaches
are silica membrane column-based kits and/or organic extrac-
tion and precipitation-based kits. One of the earliest studies
that systemically compared methods evaluated seven diﬀerent
extraction protocols and concluded that there were major
diﬀerences in yield, purity and size distribution of the RNAs
extracted by the kits.111 Nowadays there is a plethora of com-
mercial kits available from many diﬀerent companies, specifi-
cally tailored for EV isolation and subsequent RNA extraction.
Each method has its own peculiarities and attention must be
paid when comparing results from diﬀerent studies, taking
into account the EVs and RNA isolation strategies employed.
Another important source of bias relates to the possible co-
purification of non-vesicular nucleic acids bound to the exter-
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nal surface of EVs. To avoid this and isolate only intra-vesicular
RNAs protected by the lipid membrane, ISEV recommends
before RNA extraction performing a proteinase treatment first
to eliminate protein complexes that may also protect RNAs
from enzymatic degradation, followed by RNAse treatment.112
However, residual RNase activity may also damage RNA upon
extraction of the luminal contents. Consequently careful con-
sideration of the aim of the study should be first taken into
account prior to RNase treatments.
The major drawback of working with EV-derived RNA,
especially in the case of those isolated from biofluids, is the
poor RNA yield, which is often below the detection limit of
current quantification techniques such as fluorimetry (Qubit)
and capillary electrophoresis (Bioanalyzer). One possible way
of overcoming this limitation is normalizing all samples by the
initial biofluid input volume used for extraction, and vacuum-
concentrating all the extracted RNA for downstream analysis.
Suggestions to improve EV-RNA yield include diluting biologi-
cal fluid prior to extraction113 and also the observation that
more starting material is not necessarily advantageous due to
potential over-loading of sample in column based extraction
methods.114 Despite the fact that more EVs are present in
serum, plasma is more commonly studied due to the absence
of EVs released by platelets during the clotting response.115
5.1.2 Microarray analysis. Microarray technology enabled
the seminal discovery in 2007/2008 of RNAs contained in vesi-
cles derived from mast cell lines116 and glioblastoma primary
cells as well as patient serum samples.117 These studies used
gene expression arrays and first identified thousands of tran-
scripts in EVs, including miRNAs and mRNAs.116,117 The
mRNA molecules were shown to be functional, leading to
protein production in the recipient cells upon transfer of the
EV-cargo.117
5.1.3 Quantitative reverse transcriptase-PCR (qRT-PCR)
and PCR arrays. Similarly, several studies used quantitative
real time PCR-based arrays to profile the RNA content of
EVs.118–121 This is by far the most widely used method to
evaluate and quantify the miRNA content of EVs, due to the
low requirements of starting RNA (as little as 1 ng total RNA,
using a pre-amplification protocol), the ability to evaluate hun-
dreds of miRNAs of interest and the straightforward analysis
of the data that requires simple calculations and no bioinfor-
matics. As most studies that evaluate the RNA-content of EVs
aim to identify biomarkers, qRT-PCR is a good, low-cost and
reliable tool. The major drawback of this approach is the need
defining a priori the list of possible markers, as their evalu-
ation depends on the probes/primers available in the selected
platform.
During the qRT-PCR procedure per se, one of the most
important factors is the amount of starting molecules. When
direct quantification of EVs cannot be performed, the normali-
zation of the input to volume of sample input is rec-
ommended.122 Moreover, in an attempt to enhance the
amount of amplifiable molecules, pre-amplification methods
can be used,123 with no apparent bias. Despite the qRT-PCR
approach used (specific probes or non-specific DNA dyes),
results can be strongly biased according to the selected nor-
malization method. A major issue is the absence of known
endogenous controls to be used for qRT-PCR. In this sense,
the Sample and Assay Standards Working Group of the
Extracellular RNA Communication Consortium (ERCC),
recently suggested the use of spike-in controls to properly nor-
malize the RNA populations43 an approach that has been suc-
cessfully used.124
5.1.4 Next generation sequencing (NGS). Recently, the RNA
content of EVs from diverse sources has been characterised by
next generation sequencing (NGS), allowing a more compre-
hensive analysis of the EV-RNA repertoire.125–128 The predomi-
nating view is that EVs are enriched in small non-coding
RNAs, such as miRNAs, tRNAs and miscellaneous structural
RNAs such as Y-RNAs, vault RNAs and SRP-RNAs.129 This may
be due to the fact that the majority of studies have focused on
the small RNA fraction of the transcriptome, by performing
either a gel- or bead-based size selection step that limits the
analysis to small RNAs (<200 nucleotides).129–132 In this way,
researchers have bypassed the issue of sequencing abundant
rRNAs, but have consequently missed out on the identification
of mRNAs and long RNAs that oﬀer great potential as bio-
markers. One study that performed whole transcriptome ana-
lysis of EVs derived from breast cancer cell lines found 97% of
reads were derived from rRNA and argued that EVs are
enriched in rRNA molecules that are fragmented and therefore
do not appear as peaks on Bioanalyzer analysis.133 Likewise, in
another study with EVs derived from epidermoid and hepato-
cellular carcinoma cell lines, the authors found 92% rRNA,
but as they chose not to perform any size selection step they
only analysed RNAs greater than 50 nt, which therefore pre-
cluded the identification of miRNA molecules and some other
small RNAs.134 In another recent study with EVs isolated from
human pleural eﬀusion and plasma, mRNA amplification was
performed using oligo dT primers, restricting the analysis to
the poly-adenylated fraction of transcriptome.135 An unbiased
characterization of the complete vesicular transcriptome is
currently lacking, mainly due to methodological constraints
that require diﬀerent library construction protocols for small
or long RNA analysis wherein size selections limit the analysis
to specific transcript fractions. The limited RNA yield that is
obtainable from EVs, particularly those derived from biofluids,
oftentimes prohibits the construction of more than one library
per sample, not to mention the high costs involved. The
depletion of rRNA before sequencing has not been possible
also due to limited RNA yield, as the majority of commercial
kits require at least 100 ng of RNA input, or has been
attempted but was not successful to the fact that fragmented
rRNA hinders probe-based capture.133
Crescitelli et al. compared the RNA profiles of apoptotic
bodies, microvesicles and exosomes isolated by UC from the
conditioned medium of three diﬀerent cell lines.11 However,
authors only undertook a Bioanalyzer analysis, which limits
the results to RNA size profiles. This could be misleading as
typical 28S and 18S rRNA peaks will not be visible if the rRNAs
are present as fragments inside EVs, which has been reported
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by NGS data.133,134 Nonetheless, Crescitelli et al. found that
rRNAs are more prevalent in apoptotic bodies, and increases
after TRAIL-induced apoptosis. This observation may perhaps
explain the variability of rRNA content of EVs reported in the
literature, and highlights the importance of reporting cell via-
bility in studies, when applicable. The variability in quantities
of rRNA reported is discussed by Mateescu et al. in an ISEV
position paper, and they mention that ribosomes present in
extracellular fluids may become associated with EVs during
centrifugation and co-isolate at high g-force.136 They conclude
that the only way to eﬀectively prove if a particular RNA
species is truly inside EVs is by RNAse protection assays after
proteinase treatment. Therefore, it is our view that the best
description of the whole EV-transcriptome would require the
depletion of apoptotic bodies by several steps of lower-speed
centrifugations followed by pelleting of EVs at higher g-forces
and RNase digestion of intact EVs.
Despite the above-mentioned technical hurdles, NGS is the
most comprehensive tool for the analysis of transcriptome, as
it allows the unbiased view of all molecule types in a sample
and permits not only quantification, but also the identification
of mutations, and structural variations such as alternative spli-
cing isoforms, circular-RNAs and translocations.128 However,
the limitations of this method include its relatively high-cost,
the requirement of large amounts of starting RNA (usually
above 100 ng), and the dynamic bioinformatics pipelines to
evaluate the results.
5.1.5 Digital droplet PCR (ddPCR). Digital droplet PCR
(ddPCR) is a relatively new technology that allows the absolute
quantification of gene expression. By partioning PCR amplifi-
cations into thousands of fractions, this methodology allows
very sensitive detection of RNA expression levels and DNA var-
iants without the use of standard curves. Recently ddPCR has
been applied to the study of plasma-derived exosomal RNA
from prostate cancer patients137 and EVs derived from serum
and CSF of glioma patients.138 ddPCR is also very useful to
validate NGS findings, even more so in the case of EV tran-
scriptome analysis, as standard qRT-PCR depends on normali-
zation to the expression of levels of endogenous controls, and
in the case of vesicle-derived RNAs such controls are not
ubiquitous.
5.1.6 Bioinformatics analysis of the EV-transcriptome.
After generating the sequences by NGS, the computational
analysis is straightforward with no relevant deviations from
routine bioinformatics protocols. Normalised count-based
diﬀerential expression analysis is performed over the RNA
sequencing data, after removing artifacts and low quality reads
usually using the FastQC139 tool, which is able to report infor-
mation related to the GC content, the presence of adaptors,
over represented k-mers and duplicated reads, PCR artifacts or
contaminations. Reads derived from fragments of ribosomal
RNAs are usually removed in this step as well. Next, one key
aspect is to deal with distinct read-length distribution. To over-
come this issue, the alignment step could be performed by
using one or the combination of the mapping tools, such as
Burrows–Wheeler Aligner (BWA),140 Bowtie2141 or STAR.142
After the alignment is carried out, the mapped reads are used
to estimate gene and transcript expression and, the simplest
approach is to quantify raw counts of mapped reads using pro-
grams such as FeatureCounts143 or HTSeq-count.144 To facili-
tate transparent comparison of transcript levels both within
and between samples it is of utmost importance to use metrics
that attempt to normalize for sequencing depth and gene
length. The fragments per kilobase of exon per million reads
mapped (FPKM)145 and RNASeq by Expectation Maximization
(RSEM) software146 are the most used ways to normalize the
count data from RNA-seq platforms. The analysis of diﬀeren-
tially expressed genes (DEG) follows the above-mentioned
steps and the popular methods for DEG are DESeq147 and
EdegR148 DGE data can be visualized as MAPplots (log ratio ×
abundance), Volcano plots (fold change × statistical signifi-
cance), heatmaps and scatterplots. Further analysis steps
include the functional profiling in which DEG are involved.
Nevertheless, the characterization of the molecular function
requires the availability of functional annotation data for the
transcriptome under study. Gene Set Enrichment Analysis
(GSEA) is one the most common knowledge-based methods
for interpreting genome-wide expression profiles.149 Many of
the tasks shown in this section are embedded in the
Bioconductor150 a flexible software-engineering environment
that enable genome-scale analysis of high-throughput data.
5.2 Characterisation of EVs content: protein
The protein cargo of EVs is cell- and disease-type dependent,
and confers particular features to these vesicles influencing
their biological properties.71,151,152 Protein components of EVs
that are derived from diﬀerent cell types and biofluids have
been widely described using Western blotting, proteomic
technologies and fluorescent-activated cell-sorting.153–155
5.2.1 Western blotting. Western blotting for the so-called
EV markers is often used as a confirmation of EVs presence in
samples of interest.96,156 Commonly used markers include
CD63, Alix, Tsg101 and HSP70.157,158 A common mistake in
the literature is the attempt to classify isolated EVs according
to the presence of certain markers, in particular the presence
of markers such as CD63, to annotate exosomes. There are two
major problems with this approach: firstly, most EV isolation
methods will isolate a mixed population of exosomes and
microvesicles, and secondly, there are no widely accepted,
reliable markers to distinguish between these two popu-
lations.71 In addition to the fact that there are further sub-
populations of EVs within these two subsets. Indeed, Kowal
et al. found that CD63 is present in EVs, which are larger than
exosomes and that the common exosome markers HSP70, flo-
tillin-1 and actin are present in all EVs sizes.158 Furthermore,
they found that other markers, including Tsg101, were present
in only a subset of exosome-sized EVs, suggesting that these
are not suitable as generic ‘exosome’ markers. One limitation
of this study, however, was that it focused only on dendritic
cell EVs, and it is impossible to draw conclusions about uni-
versal EV markers without more extensive studies. Indeed,
Yoshioka et al. found that there was variation in the presence
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of EV markers such as CD63, flotillin-1 and HSP70 even within
diﬀerent prostate cell lines157 while CD9 and CD81 were uni-
formly present. The variability among diﬀerent prostate cell
lines may reflect prostate-cancer heterogeneity and it is well
known that cancerous cell lines can secrete EVs with diﬀerent
cargo from their non-cancerous counterparts,68,159 yet many
commonly used cell lines are cancer cell lines and information
taken from these cells taken to infer universal EV-markers will
probably be misleading. More research is needed to identify
reliable EV markers. However, it remains to be seen whether
universal EV markers in fact exist and could be used across all
mammalian cells and, furthermore, whether markers will be
found to reliably distinguish exosome and microvesicle popu-
lations. Showing the relative enrichment of several marker pro-
teins in isolated EVs compared to their corresponding whole
cells is probably a good way of confirming the presence of EVs
in the absence of better tools.
Another point to note is that most of the common EV
markers are also abundant or detectable in whole cells157 so
confirming their presence in isolated EVs is not necessarily a
good method of demonstrating sample purity. It is therefore
essential to also show negative control Western blots96,156 for
proteins such as calnexin or histones which can be confidently
expected not to be secreted in EVs; showing the absence of
abundant whole cell proteins is an important step towards
proving that isolated EVs are not contaminated by cell debris.
A more general problem is that all the research discussed
above fails to address EV markers in non-mammalian cells,
which may have an entirely diﬀerent set of EV markers even if
mammalian markers are present in the genome. EVs are
studied from bacteria,160 to algae,161 helminths162 and proto-
zoa163 and have important implications in basic biology. An
alternate, unbiased way of showing protein loading and dis-
tinct protein composition from whole cells without the need
for specific markers is to use protein staining instead of
Western blotting, such as silver or SYPRO Ruby staining.164
5.2.2 Proteomics. Undeniably, mass spectrometry based
proteomic analysis has increased our knowledge about the
protein content of EVs. In particular, bottom up mass spec-
trometry-based proteomics has been used worldwide as the
strategy of choice. In this approach proteins are extracted from
a biological source, digested into peptides that are sub-
sequently separated by 1D or 2D gel electrophoresis (gel-
based) or liquid chromatography (gel-free) and analysed by
mass spectrometry. Peptide ions are fragmented in the gas
phase and their sequence and post-translational modifications
(PTMs) can be deduced. Protein quantification can be achieved
using diﬀerent strategies depending on the study aims.165 In
particular, shotgun proteomics approach allows a discovery-
driven protein identification and quantification where peptide
ions are measured and heuristically selected for fragmentation
using a data-dependent mode.166 In targeted proteomics, only
predetermined peptide ions are selected for fragmentation
allowing a hypothesis-driven protein detection and quantifi-
cation. Several acquisition methods have been implemented
for targeted proteomics such as selected reaction monitoring
(SRM)167 pseudo selected reaction monitoring (pSRM)168 and
parallel reaction monitoring (PRM).169,170 Another approach is
the data-independent acquisition in which no precursor ion
selection occurs and all precursors are fragmented.171–173 The
resulting MS/MS spectra are commonly searched using spec-
tral libraries171 or novel computational frameworks.174 These
proteomics strategies have been used in several EVs character-
ization studies and excellent reviews on EVs isolation and pro-
teomics have been published.175–177 As such, we will focus on
the use of mass spectrometry-based protein analysis and pro-
teomics technologies to better understand the more specific
diﬀerences in the EV proteome such as post-translational
modification (phosphorylation and glycosylation).
5.2.3 Post-translational modifications in EVs: a path to
explore. Mass spectrometry analysis allows quantitative protein
profile of EVs in diﬀerent conditions. Still, there are additional
layers of protein regulation, such as PTMs that modulate
protein structure and function changing its physicochemical
characteristics, interaction partners and activity.178
Protein glycosylation is one of most widespread PTMs,
which involves the enzymatic attachment of a glycan moiety to
a protein, occurring mostly in the ER and Golgi. Indeed,
protein glycosylation has been shown to play an important role
in cancer, diabetes, neurodegenerative and cardiovascular dis-
eases.179 Several glycan binding proteins were identified in
EVs such as CD62, found in isolates from activated platelet5
and several members of the galectin family.180,181
Protein phosphorylation is a very dynamic PTM catalysed by
kinases and reversed by phosphatases that regulates several
signalling events both extra- and intracellularly. Even though
most reports have applied immunodetection techniques to
study protein phosphorylation in EVs, Gonzales et al. have
described a large-scale phosphoproteomic approach to exo-
somes isolated from urine that allowed the identification of 14
phosphoproteins, such as AQP2, which was confirmed by
immunoblotting.182
Since regulation of cell function is achieved through an
intricate network of PTMs, it would be desirable to study
several PTMs simultaneously. Although mass spectrometry-
based proteomics has allowed the comprehensive identifi-
cation of PTMs and their crosstalk,183–185 bioinformatics ana-
lysis and functional interpretation of multiple PTMs remains a
challenge. However, we believe that increasing comprehensive
multiple PTMs studies will help shed some light in EVs PTMs
cross-talk and burst the discovery of novel signalling
mechanisms.
5.3 Characterization of EVs content: lipids
Structurally and functionally, lipids represent an extremely
heterogeneous group of molecules, defined by various permu-
tations of head-groups and fatty acid chains, which together
define lipid structure, head-group polarity, and hydrophobi-
city. Due to often limiting amounts of sample available and its
high complexity, mass spectrometry-based approaches oﬀer
high sensitivity and specificity that is essential for the analysis
of EV-lipidome. Modern mass spectrometers oﬀer high resolu-
Nanoscale Review
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tion and high mass accuracy of survey scan, thereby providing
the required accurate mass measurement of the lipid mole-
cular weight. However, partial or complete overlap in the
elemental compositions between lipids of diﬀerent classes
imposes a great challenge for their confident identification.186
Lipid content can be analysed from EV pellets reconstituted
in aqueous environment after their UC, or from highly concen-
trated EVs size exclusion chromatography fractions. Typically,
the lipid amount used for analysis is expressed relative to
protein quantity, and may vary from 100 µg protein equivalent
or more.187,188 EV lipids are most commonly extracted using
Bligh and Dyer189 and Folch190 liquid–liquid extraction, where
lipids are enriched in the lower organic layer of chloroform/
methanol/water phase. However, both methods carry a risk of
contamination by protein from the upper aqueous phase
during the collection of organic phase, which may have dele-
terious eﬀects to the downstream nLC/LC-MS/MS analysis.
Additionally, due to the hydrophobic nature of chloroform,
both methods may discriminate extraction of partially polar
lipids and additionally challenge their detection. Recently
methyl-tert-butyl-ether (MTBE) extraction of lipids was demon-
strated to extract almost all lipid classes form highly complex
biological samples with equivalent or better recoveries than
the “gold standard” Folch extraction.191 To date, lipidomic pro-
filing of EVs derived from diﬀerent cells,187,192 species193 and
biological tissues194,195 have been published, together with
recent reviews on lipidomics of EVs.176 Since EVs are cell-
derived particles, their lipid composition is related to its
parent cell. Eventhough, a direct comparison of the lipid
profile between exosomes and plasma membrane of the releas-
ing cells allowed the identification of specific lipid classes that
appear to be enriched in the exosomal fraction. Membranes of
typical EVs are mainly enriched in fully saturated glycerophos-
patidylcholines, glycerophospatidylethanolamines and glycero-
phospatidylserines, that are responsible for membrane rigidity
and integrity, and sphingomyelin, cholesterol lipids and
ganglioside GM3.196 A study characterized more than 280 lipid
species from metastatic prostate cancer cell-line derived exo-
somes. Exosomes were enriched in glycosphingolipids, sphin-
gomyelin, cholesterol, and phosphatidylserine indicating a
particular lipid sorting in the exosome membrane.197
Although lipid content of EVs attracts increasing attention, not
much is known about their biological activity. Sphingomyelin
is reported to mediate antigenic activity of tumour-derived EVs
both in vivo and in vitro.74 Lysophosphatidylcholines in EVs
derived from mature dendritic cells appear to act via G-protein
coupled receptors and trigger lymphocyte chemotaxis.198
5.4 Characterization of EVs content: metabolites
During EV formation, small metabolites such as sugars, amino
acids, nucleotides, diﬀerent enzymatic cofactors, lipid metab-
olites and other redox regulatory molecules can be packed into
EVs. Sub-nM concentrations of metabolites and low sample
amounts impose a great challenge for the metabolomics of
EVs, which may be one of the reasons why this type of analysis
is only sporadically reported.199–201 Metabolites comprise a
broad array of small molecular weight analytes, derived as
intermediates and products of enzymatically-driven cellular
processes. Due to their smaller size, metabolites are character-
ized by their lower hydrophobicity compared to lipids. Thus,
they are usually enriched via extraction from vesicle pellets
with methanol or methanol/water. However, co-extraction of
highly abundant lipids may suppress ionization of metabolites
of interest and greatly challenge their detection even with the
most sensitive targeted mass spectrometric detection. Thus,
metabolites of interest are further enriched using solid phase
extraction (SPE) cartridges. The choice of SPE chemistry
depends solely on the analyte chemical nature and eluting
condition. The most common conditions include loading of
sample in 10% aqueous methanol (pH 2), hexane washing of
hydrophobic lipids, and elution of metabolites in methanolic
ethylacetate or butylaceta.199,201 Eluates are further vacuum
dried and can be stored at −20 °C, or analysed immediately by
mass spectrometry.
Although information of the metabolome of EVs is limited,
all published studies to date support the significance of EVs as
carriers of important metabolome fingerprints which can be
used for defining specific changes in cellular homeostasis.
Increasing evidence suggests that, during defined stages of the
acute inflammatory process, neutrophil-derived EVs carry
specific enzymatically-derived polyunsaturated fatty acid
(PUFA) metabolites such as 4-, 7-, 14- and 17-hydroxy-docosa-
hexaenoic acid, 5-, 12-, 15-hydroxy-arachidonic acid, 12-, 15-
and 18-hydroxy-eicosapentaenoic acid and others.199,201 These
metabolites are of particular importance because they serve as
direct precursors of anti-inflammatory and pro-resolving lipid
mediators,202 such as resolvins, maresins, protectins and
lipoxins. Prostaglandin (PG) rich vesicles trigger PG-dependent
intracellular pathways in the host cells.203 Thus, depending on
the metabolome cargo, EVs in target cells can induce for-
mation of pro-inflammatory, or anti-inflammatory and pro-
resolving lipid mediators, and thereby influence inflammatory
outcomes and tissue homeostasis.
Metabolomics is an emerging technique with focus on
identification and quantification of a wide variety of small
molecules which may be indicative of physiological status in
health and disease. Metabolites are produced in vivo, usually
via enzymatically-driven processes; thus their circulating levels
are very low, and often out of the reach even for the most sensi-
tive detection techniques. Thus, analysis of EV-metabolome
relies on a careful and well-designed sample enrichment, and
sensitive MS-detection. Recently some authors200 for the first
time described methodology for the LC-MS/MS profiling of
blood plasma EVs, and EVs derived from cultured cells.
Coenzyme Q10, ubiquinone 9,25-hydroxy-hexadehydrovitamin
D3, malonyl-CoA, deoxyvitamin D3 and others, are only some
of identified metabolites that belong to the wide range of
metabolite classes. However, MS-profiling often does not oﬀer
the sensitivity necessary for detection of very low abundance
metabolites. Targeted mass spectrometry (e.g. multiple reac-
tion monitoring, MRM) provides necessary sensitivity and
specificity, however it discriminates detection and identifi-
Review Nanoscale
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cation of those metabolites that are not “targeted” by designed
acquisition methods, and cannot be used for wide-band meta-
bolome profiling.204
5.4.1 Bioinformatic tools used in lipidomics and metabolo-
mics. Comprehensive analysis of large lipidomics and meta-
bolomics data-sets is a challenging and time consuming task.
Although significant improvement in the field has been made
over the past few years, identification of lipids and metabolites
is still not as straightforward as protein identification.205 The
LIPID MAPS (http://www.lipidmaps.org) is a free of charge
online platform for the analysis of MS data based on their
accurate mass measurement.206 Recently, LIPID MAPS have
implemented a search tool that uses precursor or product ion
lists and matches them with thousands of diﬀerent lipids with
in silico-generated structures or those present in the database.
The Human Metabolome Database (http://www.hmdb.ca) is a
freely available database that accounts for 42 003 metabolites
found in the human body and supports analysis of MS, MS/MS
and GC-MS data uploaded in a form of peak lists.
LipidXplorer-assisted analysis of large shotgun lipidomics data
sets is used routinely for lipid identification, independently of
any resource of reference mass spectra, and solely based on
assumed molecular fragmentation pathways.207 The software
and MFQL library are free for download (https://wiki.mpi-cbg.
de/lipidx/Main_Page) and can be used regardless of the mass
spectrometer type. It is important to note that the mass resolu-
tion and accuracy influence strongly unequivocal lipid identifi-
cation. Lipid View (ABSciex) and Progenesis QI for small mole-
cules (Waters) are commercially available platforms. Both soft-
wares can use MS and MS/MS that they match against publicly
available and in-house databases.
Although many diﬀerent MS platforms for lipid analyses
are available nowadays, analysis of EV-bound metabolites and
lipids remains a significant challenge. Very low amount of
sample still imposes the greatest challenge for EVs wide-band
profiling. To date, both analyses have already advanced our
knowledge on biomolecular composition of EVs and helped us
better define their structure-to-function relationship.
Nevertheless, further advances in lipidomics and metabolo-
mics are necessary to allow application of MS for the analysis
of EVs derived from various diﬀerent sources and biological
tissues. The main technical pitfalls of working with EVs and
potential ways to avoid them are summarized in Table 1.
6 In vivo studies of EV-function
The ability to discriminate vesicle populations of interest from
the general EV pool in tissue compartments and bodily fluids
remains technically challenging. The cellular origins of EVs,
their route of administration, their concentration and their
mode of targeting significantly impacts on EV bio-distri-
bution.224 However, non-traditional routes of EV adminis-
tration, such as orally administered EVs have shown uptake via
the intestinal mucosal surface and subsequent accumulation
in the liver and spleen.225 Irrespective of administration route,
a key outcome measure is biodistribution, to trace where
exogenously applied EVs go after they have been introduced
into an animal.
Fluorescent labelling of cellular proteins have revolutio-
nized in vivo studies of cells. However, similar protein marker
tracing of EV through EV-associated proteins like CD63-GFP
(green fluorescent protein) have been shown to be an eﬀective
detection approach. A fraction of EVs is CD63-positive and
further work is required to establish the cellular processing of
CD63 on EV populations. Numerous protein markers (CD63,
TSG101, Alix and heat shock proteins) are widely reported as
associated to EVs but their overall contribution to the total EV
population remains contentious. Therefore, utilising these pro-
teins as imaging or labelling moieties requires caution. The
nanometer-size scale of EVs presents challenges in studies
that require spatiotemporal resolution. In addition, exosomes
may be as small as 50 nm in size and tagging them with a
5 nm GFP molecule may significantly aﬀect both their biodis-
tribution, kinetics and their functional eﬀects.
Secondary labelling of isolated EV using lipophilic dyes
(DiR (1,1-dioctadecyl-3,3,3,3-tetramethylindotricarbocyanine
iodide, D12731, Invitrogen, Life Technologies, PKH26/67
Sigma-Aldrich or Dil Stain (1,1′-dioctadecyl-3,3,3′,3′-
tetramethylindocarbocyanine perchlorate (‘DiI’; DiIC18(3)))
Thermo)) have shown distribution to the spleen, liver, lungs,
pancreas, kidneys and gastrointestinal tract. These lipophilic
methods are limited in scope and require the harvest of
tissues of interest for analysis, or the use of highly sensitive
cameras. Lipophilic dyes may persist in organs and tissues
after EV degradation or may associate with other lipids.
Injected liposomes that model the EV-population are rapidly
cleared from the circulation by the spleen and liver <1 hour
after injection, suggesting diﬀerences for EV/liposomes clear-
ance based on lipid profiles;226 whereas Gaussia luciferase
combined with metabolic biotinylation greatly enhances the
spatiotemporal resolution of EV tracing in vivo.227
Whilst labelling and re-applying EVs in vivo enables the
investigation of distribution, there is still a paucity of knowl-
edge regarding the downstream eﬀects of these EVs, or even
whether the numbers injected are physiologically relevant.
Indeed, the rapid generation time of both species, combined
with an easily manipulated genome, makes them ideal for
studying both the role of EVs in development, as well as the
mechanistic underpinnings of their release. It is even possible
to study the eﬀect of EVs on stereotypical behaviours in invert-
ebrates; for example Wang et al., 2014228 have shown that
ciliary EVs are responsible for the tail-chasing behaviour seen
in some worm species.
However, detailed investigations utilising vertebrates are
needed to further test the biodistribution of EVs and ascertain
the optimal route of administration for target organs or
tissues. Rodents, which are traditionally used in preclinical
research, provide rapid breeding cycle, complete genome
sequence and some physiological similarities to humans. Two
key biodistribution studies in rodents were carried out by
Xandra Breakefield’s and Samir El Andaloussi’s group, both
Nanoscale Review
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Table 1 Potential technical pitfalls, recommendations and remaining challenges according to diﬀerent techniques of EVs isolation and characterization
Sample type/technique Potential pitfalls Recommendations Remaining challenges
Pre-analytical
factors
Cell culture conditioned
medium
Presence of contaminating bovine vesicles and
proteins from FBS leading to misinterpretation
of EV quantification/characterisation
The use of EV-depleted FBS is
recommended208
Much needed standardisation of protocols
by the EV-community; current lack of
knowledge regarding serum starvation
stress over optimal duration of EVs
production, concentration and content
Use of EV-depleted FBS209 or serum star-
vation210 may stress cells leading to alterations
in EVs concentration and content
In the case of complete serum removal,
cells should be assessed for stress
induction that could alter EVs
characteristics. Autophagy, apoptosis and
necrosis should be monitored
Blood Artificial inflation of EVs counts ex vivo as a
result of platelet activation due to blood
collection, blood transportation and excessive
delay in plasma separation
Follow guidelines such as those from the
International Society on Thrombosis and
Haemostasis, including citrated tubes for
blood collection, and adequate separation
of platelet-free plasma using two rounds of
centrifugations immediately after blood
collection. Abundant proteins (such as
albumin and immunoglobulins) should be
depleted
Diﬃculty applying rigorous blood
collection and plasma separation/storage
in a large-scale clinical setting
Changes in EVs counts/cargo observed are not
related to particular disease/phenotype being
investigated, but are rather due to other clinical
and environmental factors that influence EVs
counts such as age, gender, circadian-clock,
medications, fasting state, hormonal status,
presence of infection, etc.; abundant proteins
may hamper the identification of bona fide EV
protein cargo
Compare with a matched control group
without disease and try to normalize as
much as possible the diﬀerences between
individuals within a group, controlling for
all factors cited
Unmet need for technological advances
that allow disease-specific EVs to be
isolated, quantified and characterized
separately from all other normal-cell-
derived EVs
Urine Membrane-bound proteins could be aﬀected by
proteases in the urine; EVs may remain
attached to the collection tubes
Urine should be collected in tubes
containing protease-inhibitors; containers
should be vortexed to avoid EVs being
adhered to tube wall; abundant proteins
(such as uromodulin) should be depleted
Handling of large volume samples and the
need to concentrate urine for the adequate
isolation of EVs challenges its use in a
clinical setting
EV isolation
protocols
Ultracentrifugation (UC) Variability in sedimentation eﬃciencies, no
absolute separation of EVs subpopulations.
High centrifugal forces may lead to EVs
aggregation and disruption of larger EVs; lower
centrifugal forces reduce recovery of smaller
EVs
Low-angle fixed-angle rotors provide better
separation eﬃciency211 and reducing bio-
fluid viscosity prior to centrifugation
improves recovery;113,212 protocols need to
be adjusted according to the targeted EV-
subtypes
There is a lack of methods to allow the
precise assessment of EV damage and the
recovery of the full range of EVs
Co-sedimentation of protein, lipoprotein and
RNA aggregates as well as viral particles
Combine ultracentrifugation with density
gradients to further purify samples66
Density gradients (DG) Sample fractionation leads to EVs being
divided into numerous sub-samples
Ensure higher initial EV counts due to
substantial dilution of EVs among the sub-
samples
Ultracentrifugation steps as well as the
preparation of the gradient are time
consuming; the process is laborious and
diﬃcult to be implemented in a clinical
setting
Immunoaﬃnity Concentrated EV samples are required in small
volumes
Spin columns, precipitation and other
methods can be used to reduce sample
volume
Clearer definition of EV subpopulations
and their characteristic markers. Less
aggressive dissociation of EVs from beads
to avoid aﬀecting functionality.
Minimizing antibody contamination and
buﬀers’ interference
Markers must be pre-selected by the user Characterise markers specific to EVs in the
system of interest, it has however been
demonstrated that markers vary between
EVs of interest213
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Table 1 (Contd.)
Sample type/technique Potential pitfalls Recommendations Remaining challenges
Saturation of beads with abundant, non-EV
proteins found in biofluids. Elution of EVs
from beads might damage the structure of
vesicles. Captured vesicles might not retain
functionality after elution. Eluted antibodies or
antibody remnants and harsh elution buﬀers
might interfere with downstream analysis
Coat beads to minimise non-specific
adsorption of abundant proteins from
serum samples214
Commercial kits Contaminating non-vesicular molecules (such
as protein, protein aggregates, lipids and free
nucleic acids) may occur in all isolation
methods, but may be more predominant here
due to precipitation process
Evaluate the more prevalent non-vesicular
contaminants of the sample under
investigation and test kit to establish
optimal protocol for experimental aim
The unknown biochemical basis of many
kits restricts our ability to fully understand
EV populations extracted and the non-
vesicular contaminants
Potential interference by elution buﬀers in
downstream applications
Include controls in functional tests
checking the eﬀects of kit elution buﬀers
on cells receiving EVs
Size exclusion
chromatography (SEC)
Inability to concentrate diluted EV sample,
which, often requires second step i.e. re-
concentration of EVs by
ultrafiltration56,80,81,83–86
To rapidly concentrate EV fractions the
application of protein concentrating
devices is recommended
Concentrating devices need to be
standardized in order to allow results to be
comparable across studies
Ultrafiltration (UF) Non-specific binding of EVs to column
membranes leading to reduced yield owing to
trapping in filter pores35,56
Ultrafiltration coupled with SEC is
recommended for enhanced EV purity,
preserving their properties56,60
Forcing vesicles through filters might
damage larger EVs whereas the use of less
force, through gravity or by using less
pressure makes the process longer and less
adequate in some cases40
Characterisation of
isolated EVs
Electron microscopy (EM) Dehydration and fixation of EVs during
processing may disrupt membranes leading to
artefacts
Use cryo-EM in combination with
immunogold labelling, where samples are
not dehydrated215
Development of new methods both
quantifying and characterising EVs. No
currently available EM approaches for
routine analysis of EVs in a clinical
scenario
Inability to readily discern heterogeneous EV
populations
Use of alternative super-resolution
microscopy techniques i.e. PALM216 or
STORM217
Nanoparticle tracking
analysis (NTA)/resistive
pulse sensing (RPS)
Resuspension buﬀers may contain particles
misinterpreted as vesicles
Include controls to ensure that EV
suspension buﬀers analysed in order to
establish a control/background
Polystyrene bead refractive index not
identical to that of EVs. Current issues in
discerning clustered from non-clustered
vesicles, especially in samples of higher
EV-concentration (NTA). Establishment of
lower detection limit for RPS
Accuracy in reporting size and concentration is
debatable
EVs or their contents can be GFP labelled
to ensure proper analysis.102 Bead cali-
bration should be used218
Flow cytometry (FCM) Distinction between single particle positive and
negative EV samples
Use reciprocal dilution to ensure single
particle detection or use multicolour and
multiplex approaches to resolve individual
vesicles219
High refractive index of commonly used
reference beads compared to EVs
Scatter resolution Use scatter beads of known size and
refractive index. Use fluorescence beads
with known molecules of equivalent
soluble fluorophore (MESF) units220
Characterisation of
EV contents
RNA purification Low RNA yields Normalize all samples by the initial
biofluid input volume used for extraction,
and vacuum-concentrate extracted RNA for
downstream analysis
Diﬃculty in eliminating residual RNase
that would reduce the available luminal
EVs RNA
DNA contamination in EV RNA samples DNase treatment of RNA samples should
be performed prior to downstream analysis
Non-vesicular RNA complexed with proteins
may be bound to the outside of the EV
membrane
Use proteinase followed by RNase
treatment of intact vesicles to eliminate
protein complexes protecting non-vesicular
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Table 1 (Contd.)
Sample type/technique Potential pitfalls Recommendations Remaining challenges
extracellular RNAs from enzymatic
degradation221
RNA analysis by qRT-PCR Low RNA yield, especially from clinical
samples, may hamper the quantification and
analysis of less abundant RNA populations
Pre-amplification can enhance the amount
of amplifiable molecules with no apparent
bias.123 Use spike-in controls to properly
normalize the RNA populations.124 If poss-
ible, use multiple endogenous controls
based on EV-transcriptomic data, or use
absolute quantification (by digital PCR, for
example) for validation
The technique is intrinsically limited to a
very specific set of pre-selected RNAs, not
allowing a broader view of the EV-
transcriptome
RNA analysis by NGS Library preparation issues: adapter dimers,
ligation and size-selection bias
Ribosomal RNA (rRNA) depletion may be
unsuitable due to low starting input of
RNA and presence of fragmented rRNA.
Extensive fragmentation of RNA may be
used to generate total transcriptome
library and analyse small and long RNAs
simultaneously128
Fragmentation of rRNA species hinders
eﬃcient rRNA removal.133 Excessive RNA
fragmentation can lead to diﬃculties in
properly mapping the short reads.
Comprehensive EV-transcriptional data-
bases are lacking, especially from NGS data
derived from clinical samples
Reduce adapter dimers using specific
kits50 or use fragmented RNA to minimize
artefactual adapter dimer formation and
preclude size selection128
Protein analysis Co-purification of protein, protein aggregates
and lipoprotein contaminants
Remove abundant proteins such as
immunoglobulins by combining
ultracentrifugation and protein G agarose
bead incubation,222 especially when
working with EVs derived from biofluids
The depletion of contaminant proteins
requires a significant mass which is not
always available from clinical samples.
Proteomics methods need to be developed
to accommodate the analysis of reduced
mass of protein
Heterogeneity of protein markers on diﬀerent
EV populations, for example presence of CD63,
HSP70, flotillin-1, and actin present in both
exosomes and microvesicles
Use a range of markers or non-marker-
specific methods to distinguish diﬀerences
between cells and EVs such as silver
staining or SYPRO Ruby staining164
Identification of protein markers capable
of diﬀerentiating specific EVs subtypes
Contamination of samples with cellular
components
Non-EVs proteins, such as calnexin,
GM130, cytochrome C and histones,
should be used as negative controls to
ensure purity of isolation158
Protein degradation during vesicle
manipulation
Use of protease and phosphatase
inhibitors is highly recommended during
EV protein extraction
Protease treatment needs to be
standardized according to the biofluid-
origin of the EVs under study
Lipid analysis Contamination by proteins during extraction Liquid–liquid extraction is preferred
method for EV lipid analysis.189,190 Use of
internal standards is recommended to
ensure high mass accuracy and confident
identification. If possible use LC to ensure
separation of lipids prior to sensitive MS/
MS. MTBE extraction was shown to extract
all lipid classes with better recovery than
the Folch method191
In liquid–liquid extraction protein
contamination from the aqueous phase
and bias towards extraction of partially
polar lipids may occur. Public databases of
lipids are still far from complete
Diﬃculty in extracting and representing all
lipid classes
Metabolome analysis Low metabolite yields and reproducibility (LC/
MS)
Enrich sample using solid phase extraction
prior to MS.199,201 Major lipid and protein
species should be removed in this process
to ensure sensitive MS analysis
Development of better bioinformatic
analysis pipelines for metabolites. Public
databases of metabolites are still far from
complete
Cell culture metabolite contamination Use of a cell-free medium control223
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showing that by using vertebrate species and specific labelling
techniques, it is possible to demonstrate that distribution
of EVs is determined by cell source and route of
administration.224,227
Tracing experiments to observe EVs biodistribution are
important but further emphasis must be placed on the role of
EVs in physiological systems. EVs cargo such as miRNAs have
shown regulation of physiological barriers such as the blood
brain barrier229 to promote tissue invasion and progression230
and descriptions detailing the physiological relevance of EVs
at sites of accumulation or deposition are needed.
Functional studies are much more varied and outcome
measures are group specific and will largely depend on the
scientific question at hand. Despite this, an extremely broad
range of disciplines, from basic molecular neuroscience, to
complex integrated cardiovascular physiology, are now begin-
ning to study the role of EVs in their model systems.
7 General recommendations for
working with EVs
The following general recommendations are made regarding
pre-analytical factors, EVs-isolation methods as well as the
characterization of EVs and of their content.
7.1 Pre-analytical factors
For human samples, variables such as gender, age, use of
medications, circadian-clock, fasting, etc., should be con-
trolled.231,232 For blood-derived EVs, attention should be given
to reduce platelet activation and the release of platelet-EVs. In
this sense, excessive shaking of collected blood should be
avoided and plasma is preferred over serum. Anti-coagulant
should be chosen based on the capability to reduce the release
of platelet EVs and impact on downstream applications,
helping to preserve RNA and/or vesicle integrity for in vitro or
in vivo studies: citrated tubes have been suggested for most
applications.33 Viscous fluids such as plasma and saliva
should be diluted in PBS to improve EV recovery. EVs-depleted
FBS, obtained by overnight UC (100 000g), should be preferen-
tially used for cell culture medium.41–43 Non-conditioned
medium should always be used as a negative control. For urine
samples, it is recommended that protease inhibitors are
present in the collection containers to preserve the sample, in
addition to extensive vortexing, required to recover the highest
amount of vesicles that could remain attached to the tubes
during storage.233 If not processed immediately, urine samples
should be stored at −80 °C to avoid bacterial contamination.
Pathological conditions that aﬀect glomeruli filtration and
lead to elevated urine protein loss, together with the high
levels of uromodulin, can magnify issues of protein contami-
nation and protein aggregates that make downstream EV-
studies challenging. To reduce uromodulin and protein aggre-
gates that interfere with downstream EV-studies we suggest the
use of CHAPS (3-[(3-cholamidopropyl)dimethylammonio]-1-
propanesulfonic), a mild detergent that preserves protein con-
formation and enzymatic activity,234 allowing the functional
studies of urinary EVs. As a general rule, the characterization
of the molecular content of EVs isolated from biofluids will
always benefit from depletion of high abundant non-EV pro-
teins. Albumin can be removed from plasma by the use of the
Protein Organic Solvent Precipitation (PROSPR) protocol,235
immunoglobulins in CSF can be depleted by protein G agarose
beads followed by UC.222
7.2 EV-isolation
The need of robust, standardized and reproducible EVs-iso-
lation methods is an essential requirement. As the EV isolation
method employed directly impacts the results obtained, all
samples of a study should be processed by the same method.
UC, the classic approach for EV-isolation, is not suitable for
clinical applications and may disrupt EVs when high g-forces
(>100 000g) are used.56 DG is a laborious and time-consuming
approach that does not supply high yields but usually provides
purer EVs, especially when iodixanol-based gradients are used.
In general, we recommend the use of DG when highly purified
EVs are required, e.g. for characterization of EVs subtypes, or
to determine their nucleic acid or protein content. UF is a
good approach to concentrate EVs and it is much faster than
UC, but has not been broadly evaluated. For immunocapture
we recommend the use of magnetic beads or microfluidics, to
improve the interactions between EVs and the capture anti-
bodies. However, it is not currently known if the antibody-
binding would aﬀect the functionality or the cargo of the cap-
tured EVs or whether it would introduce bias to subpopu-
lations of EVs and non-EVs contaminants. Alternative methods
such as chromatography, flow field-flow fractionation, polymer
or solvent-based precipitation, immunoaﬃnity capture and
microfluidics are useful methods to avoid the co-isolation of
lipoparticles and lipid droplets from biofluids. After isolation
the purity of the EVs should be assessed. As a reference, the
isolation of EVs using sucrose density ultracentrifugation pro-
vided about 3.3 × 1010 EVs per µg protein from conditioned
culture media (prostate, breast, bladder and mesothelioma
cells) and about 2 × 109 EVs per µg from biofluids (urine and
serum from healthy donors).92 To conclude, the selection of
the method of choice strongly depends on the type of EVs-
source and the downstream analyses and applications.
7.3 EV characterization
NTA is a valuable method for determining the concentration
and size distribution profiles of EVs. Due to its non-specific
nature, special care should be taken to ensure the particles
measured are indeed EVs. We recommend the buﬀer in which
the EV sample are suspended to be analysed separately, to
establish a background count. In addition, the use of a lipid
dye or a fluorescently labelled EV marker in combination with
the NTA fluorescence mode will reduce the impact of non-EV
particles. Similarly, eﬀorts should be taken to reduce the con-
tribution of non-EV contaminants when analyzing particles by
RPS; this could include measurement of the background par-
ticle count present in the EV buﬀer. For RPS filtration and SEC
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can prevent clogging and multiple counts are needed to
reduce the impact of variability. Furthermore, the size distri-
bution of EVs observed using either whole-mount Electron
microscopy EM, NTA or RPS should be compared to check that
they yielded similar results. For flow cytometry protocols
should be optimised and these parameters checked with
routine calibration, as well as the use of robust negative con-
trols, used to minimize the impact of false-positive signals
arising from antibodies/protein aggregates. EM is of great help
to characterize the EVs and negatively stained whole mount
EM is a relatively quick and simple technique that greatly
helps evaluating the presence, morphology and size distri-
bution of EVs. Further imaging by cryo-EM is more technically
challenging but the ability of this technique to resolve lipid
bilayers makes it the most direct way to directly confirm the
presence of bona fide membrane-bound vesicles.
7.4 Characterization of EV content
We perceive the major challenge in establishing EV content to
be related to the limited amounts of EVs that can be recovered
from biofluids. The precise description of the transcriptome of
EVs, a mixture of few copies of a complex transcriptome com-
bined with high copies of fragmented ribosomal RNA, is chal-
lenging. In order to uncover the total transcriptome of EVs,
non-EV RNAs must be removed by RNAse treatment.
Following, we recommend the use of Next Generation
Sequencing of pre-fragmented EVs-derived RNA that allows the
identification and quantification of all RNA biotypes.128 If the
aim is to simply describe the EV miRNAs a comprehensive
qRT-PCR arrays can be used, but these are limited to a set of
pre-defined molecules.
The observation of classic EV-markers in Western blots is
used to reinforce that bona fide EVs have been isolated.
However, due to the limited knowledge regarding consistent
EV-specific proteins, there is no single protein or combination
of proteins that can be recommended as universal EVs
markers. Nevertheless, we recommend the evaluation and
reporting of at least three classic EV-proteins, as their presence
or absence may be informative to the EVs characterisation. We
also suggest evaluating proteins that are not expected to be
present in EVs, as controls of contamination, such as proteins
from the endoplasmic reticulum (e.g.: calnexin), Golgi (e.g.:
GM130), mitochondria (e.g.: cytochrome C), and nucleus (e.g.:
histones).49 The addition of a protease in the presence or
absence of a membrane-disrupting detergent should help to
establish whether a protein is present inside the EVs, and
therefore protected by the EV membrane, or a secreted factor
or a co-extracted protein. Finally, the presence or absence of
particular proteins should be regarded as supporting evidence,
rather than interpreted to mean that the sample definitely con-
tains EVs or a particular EV sub-population. Large-scale
shotgun proteomics is the method of choice to characterize
more broadly the EVs-content. The application of native mass
spectrometry at the protein level characterization and cross-
linking, H/D exchange and covalent labelling at the peptide
level characterization allows understanding the exosomal
protein–protein interaction and structural modulation in
diﬀerent conditions.
LDL and HDL can be co-extracted from plasma by some EV
isolation protocols and, due to their content of cholesterol and
its fatty acid esters, as well as phospholipids, this can lead to
misleading lipid profiles, including suppressing the identifi-
cation of less abundant EVs lipids. Therefore, before perform-
ing the lipidomic profiling of plasma/serum-derived EVs, we
recommend the use of size exclusion chromatography for iso-
lation of EVs distinctly from HDL/LDL particles, which might
also be helpful to reduce the contamination with other circu-
lating lipids in biological fluids. The chemical diversity of
lipids and metabolites compounds requires diﬀerent extrac-
tion methods to be applied for lipids and metabolites.
Recently, the promising SIMPLEX protocol was used for the
simultaneous isolation of proteins, lipids and metabolites
reducing the sample amount needed for a comprehensive bio-
molecular characterization.236 The combination of diﬀerent
front-end separation techniques such as GC and HPLC using a
variety of stationary phases with high resolution and accuracy
mass spectrometers will improve the number of identified and
quantified lipids and metabolites in EVs.
8 Towards deciphering “EVome”
complexity: future directions
EVs are central elements in cell–cell communication and play
a key role in the field of liquid biopsies. These two aspects
makes their study extremely promising, and future directions
include improvements in characterizing their cargo to better
define their roles in tissue homeostasis and to better identify
the biomarkers that they carry. The full determination of the
RNA-content of vesicles will benefit from the fast growing field
of genomics, especially from the technologies that handle
minute amounts of nucleic acids, including single-cell geno-
mics and barcodes to identify individual molecules. Regarding
proteomics, the amount of protein mass has deeply decreased
allowing the identification of thousands of proteins from low
abundant samples, such as FACS-sorted cells237,238 and fine-
needle aspiration biopsies.239 Straightforward sample prepa-
ration methods and novel mass spectrometers can improve the
sensitivity and quality of protein quantitation.240 Nonetheless,
functional validation of EV proteins is needed, linking proteo-
mic information and functional studies and providing greater
overview of EV function. Moreover, combining information on
multiple omics will help in understanding the complex bio-
logical network of EVs.175,241–243
The field of EVs has gained increasing interest and knowl-
edge is rapidly accumulating. This has helped this area to
move from bench top science towards translational and clini-
cal research, including in vivo experiments as well as diagno-
sis. Nevertheless, our perception is that the field is not yet
ready for clinical applications. Therefore, we believe it is too
early to state that we can confidently interpret EV-data or
administer/manipulate EVs for clinical purposes.
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